Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 18, 2007

View Archived Issues

Avigen begins phase II trial of AV-650 for spasticity associated with MS

Sinovac begins phase II trial of influenza H5N1 vaccine

Update on Quigley's phase IIb study of QR-333 for diabetic peripheral neuropathy

S*BIO to develop JAK2-selective kinase inhibitor SB-1518

Update on SGX and Novartis' collaboration agreement for Bcr-Abl inhibitors

Update on Opexa's phase IIb study of Tovaxin for multiple sclerosis

FDA advisory committees make recommendations on development of Trasylol

Update on Alfacell's phase IIIb trial of Onconase for malignant mesothelioma

Innocoll and TGR BioSciences to collaborate on CollaRx delivered TGR-265

Novartis and Bayer Schering complete agreement on Betaseron

Cortex submits IND for Ampakine drug candidate CX-717 for ADHD

Southern Research Institute licenses anticancer compound to Virium

Aldagen raises additional funding to develop three clinical-stage products

FDA accepts NDA filing for Cleviprex in acute hypertension

GSK to evaluate option to develop Exelixis' MET inhibitor XL-880

Radius grants Novartis worldwide license option for BA-058 for osteoporosis

BioProgress changes name to Meldex International

Positive results for Novo Nordisk phase III trial of human GLP-1 analogue liraglutide

Novel agents for treating endocrine-related disorders disclosed in recent patent literature

Intrathoracic administration of telomelysin active in malignant mesothelioma

Snapshots of clinical trials in cardiology: ESC 2007

Novel candidate for hepatitis C therapy: IMO-2125

KBPA-101: suitable clinical candidate to treat ventilator-associated P. aeruginosa infections

Recent patents describe new treatments for musculoskeletal and connective tissue disorders

FDA accepts Sucampo's sNDA for lubiprostone in IBS-C

LK-157: a broad spectrum beta-lactamase inhibitor presented at ICAAC

BLI-489 shows in vitro and in vivo efficacy in combination with piperacillin

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...